Clinical research of docetaxel combined with iodized oil for the treatment of liver tumor
1. Shanghai Sixth People’s Hospital, Jinshan Branch, Shanghai Jiaotong University, Shanghai 210599, China;
2. Department of Radiology, the Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
Abstract:Objective: To explore the clinical effect of intervention programme using docetaxel combined with iodized oil in the treatment of liver cancer. Methods: Forty-three cases of primary advanced liver cancer were randomly divided into group A(docetaxel group with 22 cases) and group B (conventional therapy group with 21 cases). The patients in group A received injection of dexamethasone 10 mg to prevent allergic reaction firstly, and then docetaxel 60 mg/m2 dissolved in 100 mL of 0.9% saline was infused slowly. And finally transarterial embolism was performed with slow injection of 5-FU 250 mg and 5~20 mL iodine suspension until iodine oil deposited in the tumor foci was thick or blood flow slowed down. Patients in group B were treated with different combination of epirubicin(EADM) 40~60 mg/m2, mitomycin(MMC) 8 mg/m2, cisplatin(DDP) 60 mg/m2 or hydroxy camptothecin(HCPT) 20 mg/m2 according to the patients’ conditions, together with iodine oil. Then the short-term efficacy, the patient’s survival and the complications after treatment were compared. Results: The 6 and 12 months survival rates were 94.5%, 48.9% and 91.6%, 37.6% respectively for group A and group B, and the survival rates of the two groups were significantly different(P<0.05), while the complications in the two groups were not significantly different. Conclusion: Docetaxel-containing regimen can improve the life quality of patients with primary liver cancer compared with conventional chemotherapy treatment, and can prolong the survival of patients to a certain extent.
孔 鹏1,孟令平1,杨 斌1,王家平2. 多烯紫杉醇联合碘化油介入方案治疗肝脏恶性肿瘤的临床应用研究[J]. 中国临床医学影像杂志, 2016, 27(7): 482-486.
KONG Peng1, MENG Ling-ping1, YANG Bin1, WANG Jia-ping2. Clinical research of docetaxel combined with iodized oil for the treatment of liver tumor. JOURNAL OF CHINA MEDICAL IMAGING, 2016, 27(7): 482-486.
[1]Yang MJ, Fang ZT, Yan ZP, et al. Transarterial chemoembolisation(TACE) combined with endovascular implantation of an iodine 125 seed Strand for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis versus TACE alone: a two arm, randomised clinical trial[J]. J Can Res Clin Oncol, 2014, 140(6): 211-219.
[2]Mei QL, Li Y. Transcatheter arterial embolization of hepatic arteriovenous shunts in patients with hepatocellular carcinoma[J]. Semin Intervent Radiol, 2012, 29(5): 237-240.
[3]Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study[J]. Ann Surg Oncol, 2011, 18(3): 413-420.
[4]Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J]. Radiology, 2011, 25(8): 627-634.
[5]Zhang XB, Wang JH, Yan ZP, et al. Hepatocellular carcinoma invading the main portal vein: treatment with transcatheter arterial chemoembolization and portal vein stenting[J]. Cardiovasc Intervent Radiol, 2009, 32(6): 52-61.
[6]Zhang XB, Wang JH, Yan ZP, et al. Hepatocellular carcinoma with main portal vein tumor thrombus treatment with 3 Dimensional Conformal radiotherapy after portal vein stenting and transarterial chemoembolization[J]. Cancer, 2009, 15(6): 1245-1252.
[7]Luo J, Yan Z, Liu Q, et al. Endovascular placement of iodine 125 seed Strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein[J]. J Vasc Interv Radiol, 2011, 22(7): 479-489.
[8]Shi HB, Yang ZQ, Liu S, et al. Transarterial embolization with cyanoacrylate for severe arterioportal shunt complicated by hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2013, 36(8): 412-421.
[9]Kim YJ, Lee HG, Park JM, et al. Polyvinyl alcohol embolization adjuvant to oily chemoembolization in advanced hepatocellular carcinoma with arterioportal shunts[J]. Kor J Radiol, 2007, 8(4): 311-319.
[10]Murata S, Tajima H, Nakazawa K, et al. Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shunts[J]. Eur Radiol, 2009, 19(7): 2016-2023.